| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.06 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.06 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.06 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.077 | 0.07 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.072 | 0.07 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.07 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.068 | 0.07 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.079 | 0.07 |